Cannabinoids form a singular family of plant-derived compounds (phytocannabinoids),
endogenous signaling lipids (endocannabinoids), and synthetic derivatives with multiple …

In patients affected by Parkinson's disease (PD), up to 50% of them experience cognitive
changes, and psychiatric disturbances, such as anxiety and depression, often precede the …

Background Regulatory recommendations favor outcomes combining objective and patient
input. The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS …

Deficiencies in adult hippocampal neurogenesis have been suggested to be a possible
pathophysiological mechanism that underlies depressive symptoms that are often observed …

Background Original clinimetric analyses by the Movement Disorder Society–sponsored
revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) developers did not …

The receptor for advanced glycation endproducts (RAGE) is a pattern-recognition receptor
associated with inflammation in most cell types. RAGE up-regulates the expression of …

Among the non-motor phenomena of Parkinson's disease (PD) are depressive symptoms,
with a prevalence of 40–70%. The reason for this high prevalence is not yet clear. The basal …

Reduction of mitochondrial complex I activity is one of the major hypotheses for
dopaminergic neuron death in Parkinson's disease. However, reduction of complex I activity …

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive
loss of nigral dopaminergic neurons and by the presence of aggregates containing α …

Diagnosing Parkinson's disease (PD) before the clinical onset proves difficult because the
hallmark PD symptoms do not manifest until more than 60% of dopamine neurons in the …